Gene Supplementation in Mice Heterozygous for the D477G RPE65 Variant Implicated in Autosomal Dominant Retinitis Pigmentosa
Human Gene Therapy · 2023
DOI: 10.1089/hum.2022.240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, 2023. Verfasst von Kecia L Feathers und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Retina, Retinitis Pigmentosa. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS.
Abstract (Originalsprache)
The use of AAV-RPE65 vectors for gene supplementation has achieved spectacular success as a treatment for individuals with autosomal recessive retinal disease caused by biallelic mutations in the visual cycle gene RPE65. However, the efficacy of this approach in treating autosomal dominant retinitis pigmentosa (adRP) associated with a monoallelic mutation encoding a rare D477G RPE65 variant has not been studied. Although lacking a severe phenotype, we now find that knock-in mice heterozygous for D477G RPE65 (D477G KI mice) can be used to evaluate outcomes of AAV-RPE65 gene supplementation. Total RPE65 protein levels, which are decreased in heterozygous D477G KI mice, were doubled following subretinal delivery of rAAV2/5.hRPE65p.hRPE65. In addition, rates of recovery of the chromophore 11-cis retinal after bleaching were significantly increased in eyes that received AAV-RPE65, consistent with increased RPE65 isomerase activity. While dark-adapted chromophore levels and a-wave amplitudes were not affected, b-wave recovery rates were modestly improved. The present findings establish that gene supplementation enhances 11-cis retinal synthesis in heterozygous D477G KI mice and complement previous studies showing that chromophore therapy results in improved vision in individuals with adRP associated with D477G RPE65.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA.
- Centre for Stem Cells & Regenerative Medicine, King's College London, London, United Kingdom.
- Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
- Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan, USA.
ORCID-Profile: Debra A Thompson
Förderung
- NEI NIH HHS
Zitieren
APA
Feathers, K. L., Jia, L., Khan, N. W., Smith, A. J., Ma, J. X., Ali, R. R., & Thompson, D. A. (2023). Gene Supplementation in Mice Heterozygous for the D477G RPE65 Variant Implicated in Autosomal Dominant Retinitis Pigmentosa. Human Gene Therapy. https://doi.org/10.1089/hum.2022.240
Vancouver
Feathers KL, Jia L, Khan NW, Smith AJ, Ma JX, Ali RR, et al. Gene Supplementation in Mice Heterozygous for the D477G RPE65 Variant Implicated in Autosomal Dominant Retinitis Pigmentosa. Human Gene Therapy. 2023. doi:10.1089/hum.2022.240
BibTeX
@article{Feathers2023,
author = {Feathers, Kecia L and Jia, Lin and Khan, Naheed W and Smith, Alexander J and Ma, Jian-Xing and Ali, Robin R and Thompson, Debra A},
title = {Gene Supplementation in Mice Heterozygous for the D477G RPE65 Variant Implicated in Autosomal Dominant Retinitis Pigmentosa},
journal = {Human Gene Therapy},
year = {2023},
doi = {10.1089/hum.2022.240}
}
EUVIMED